SLC5A2 and diabetes mellitus: One key question is how the effects of SGLT-2 inhibitors compared in patients with and without T2D, and whether the findings of the completed trials support the hypothesis that SGLT-2 inhibition might be an effective treatment for patients with heart failure, including those without diabetes.